Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

4.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
4.8K
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

239
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
239
Destabilization of Microtubules01:45

Destabilization of Microtubules

2.8K
The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of chemical features for improved outer membrane permeation in mycobacteria using machine learning.

Nature microbiology·2026
Same author

AI-Accelerated Structure Elucidation of Boavistamides A-C, Cyclic Depsipeptides from a Marine Filamentous Cyanobacterium Collected in Cabo Verde.

bioRxiv : the preprint server for biology·2026
Same author

Gel Polymer Electrolyte Membranes via Slit-Coating Technology for High-Energy Lithium Batteries.

Gels (Basel, Switzerland)·2026
Same author

Erratum for Theriault et al., "Utilization of a CRISPRi-based <i>ex vivo</i> challenge model to reveal temporally dependent gene essentiality in intracellular <i>Mycobacterium tuberculosis</i>".

mBio·2026
Same author

AI-Accelerated Structure Elucidation of Boavistamides A<b>-</b>C, Cyclic Depsipeptides from a Marine Filamentous Cyanobacterium Collected in Cabo Verde.

Journal of natural products·2026
Same author

Minimum Inoculum of Resistance Assay for Evaluating Antitoxoplasmosis Compounds That Target Phenylalanine tRNA Synthetase.

ACS infectious diseases·2026

Related Experiment Video

Updated: Sep 13, 2025

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

2.0K

SuFEx-based antitubercular compound irreversibly inhibits Pks13.

Inna V Krieger1, Paridhi Sukheja2, Baiyuan Yang2

  • 1Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX, USA.

Nature
|July 31, 2025
PubMed
Summary

A novel compound, CMX410, targets Pks13, an essential enzyme in Mycobacterium tuberculosis (Mtb) cell-wall biosynthesis. This drug candidate shows efficacy against drug-resistant Mtb strains and has a favorable safety profile.

More Related Videos

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.7K
From a Natural Product to Its Biosynthetic Gene Cluster: A Demonstration Using Polyketomycin from Streptomyces diastatochromogenes T&#252;6028
09:08

From a Natural Product to Its Biosynthetic Gene Cluster: A Demonstration Using Polyketomycin from Streptomyces diastatochromogenes Tü6028

Published on: January 13, 2017

17.3K

Related Experiment Videos

Last Updated: Sep 13, 2025

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

2.0K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.7K
From a Natural Product to Its Biosynthetic Gene Cluster: A Demonstration Using Polyketomycin from Streptomyces diastatochromogenes T&#252;6028
09:08

From a Natural Product to Its Biosynthetic Gene Cluster: A Demonstration Using Polyketomycin from Streptomyces diastatochromogenes Tü6028

Published on: January 13, 2017

17.3K

Area of Science:

  • Medicinal Chemistry
  • Microbiology
  • Drug Discovery

Background:

  • Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is a leading global infectious disease.
  • Existing TB treatments require long durations and face challenges from multi-drug-resistant (MDR) and extensively drug-resistant (XDR) strains.
  • Novel therapeutic strategies targeting essential Mtb pathways are urgently needed to shorten treatment and overcome resistance.

Purpose of the Study:

  • To introduce CMX410, a novel preclinical covalent compound targeting Pks13.
  • To evaluate the efficacy and mechanism of action of CMX410 against Mtb.
  • To assess the safety and pharmacological profile of CMX410.

Main Methods:

  • CMX410 was designed as an aryl fluorosulfate (SuFEx) covalent inhibitor.
  • The compound's activity was tested against drug-sensitive and drug-resistant Mtb strains in vitro.
  • Efficacy was assessed in mouse models of Mtb infection.
  • The mechanism of inhibition involved targeting the Pks13 acyltransferase domain.
  • Pharmacological and safety profiles were evaluated, including a rat toxicity study.

Main Results:

  • CMX410 demonstrated equipotent activity against both drug-sensitive and drug-resistant Mtb strains.
  • The compound was efficacious in multiple mouse models of Mtb infection.
  • CMX410 irreversibly inhibits Pks13 by forming a beta-lactam with the catalytic serine in the acyltransferase domain.
  • CMX410 exhibited high target selectivity and excellent pharmacological and safety profiles, with no adverse effects in rats at high doses.
  • CMX410 showed favorable performance in drug combination testing.

Conclusions:

  • CMX410 represents a promising first-in-class drug candidate for tuberculosis treatment.
  • Its unique mechanism of action and favorable profile offer a potential replacement for current cell-wall biosynthesis inhibitors.
  • CMX410's potency, safety, and oral bioavailability support its advancement in TB drug development.